KLRC2 and acute myeloid leukemia: Among them, an anti-NKG2C/IL-15/anti-CD33 TriKE called NKG2C-KE that directs NKG2C+ cells to target CD33+ AML cells has shown great efficacy both in vitro and in vivo [134].